The FDA has declined to review Moderna’s flu vaccine application, citing insufficient data and questioning the product’s adherence to standard care. Moderna’s CEO defended the vaccine, asserting no safety or efficacy issues were identified, while experts expressed concerns over the lack of guidance in the review process. Amidst a backdrop of political scrutiny and declining vaccine policies, Moderna faces challenges in maintaining its market position as sales drop significantly. The company’s stock has fallen 29%, complicating its path to financial stability.
